Drug Trial Radar · NCT05244304
Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Adolescent Stargardt Disease
Last checked: Nov 19, 2026Latest source record: Jul 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
104
Actual
Start
Mar 28, 2022
Primary completion
Aug 4, 2025
Study completion Sep 11, 2025
Sponsor
- Lead sponsor
- Belite Bio, IncIndustry
- Sponsor type
- Industry
- First posted
- Feb 17, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this trial is to assesses the efficacy of tinlarebant in slowing the rate of growth of atrophic lesion(s) in adolescent subjects with STGD1
Conditions
- Stargardt Disease 1
Interventions
TinlarebantDrug
Tinlarebant drug substance is a white to off-white substance and is dispensed as a tablet for oral administration.
PlaceboDrug
Not active drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- To measure change in atrophic lesion size (definitely decreased autofluorescence, DDAF) by fundus autofluorescence (FAF) photography from baselineTime frame: Baseline thru month 24
Locations
19 sites in 11 countries. Site status is shown where the registry gives one.
Belite Study Site
Palo Alto, California
Belite Study Site
Minneapolis, Minnesota
Belite Study Site
Salt Lake City, Utah
Belite Study Site
South Brisbane, Australia
Belite Study Site
Westmead, New South Wales, Australia
Belite Study Site
East Melbourne, Victoria, Australia
Belite Study Site
Ghent, Belgium
Belite Study Site
Beijing, China
Belite Study Site
Shanghai, China
Belite Study Site
Paris, France
Belite Study Site
Bonn, Germany
Belite Study Site
Tübingen, Germany
Belite Study Site
Kowloon, Hong Kong
Belite Study Site
Nijmegen, Netherlands
Belite Study Site
Basel, Switzerland
Belite Study Site
Taipei, Taiwan
Belite Study Site
Taoyuan City, Taiwan
Belite Study Site
London, United Kingdom
Belite Study Site
Southampton, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.